Oramed Pharmaceuticals (Seite 1411)

[reaaalist]

Antwort auf Beitrag Nr.: 46.092.110 von reaaalist am 20.12.13 17:16:06

Sorry,

hier der vollständige Satz

Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January

[reaaalist]

Antwort auf Beitrag Nr.: 46.092.020 von occitania am 20.12.13 17:09:38

Es kann nur ab jetzt auf 25 $ gehen


Moin Occi

ja, schon im Januar

Company Additionally Anticipates Results from Phase 2a FDA S…

Gruß r

@kwhistler: hoffe du bist bald wieder dabei

Grüße auch nach China zu Karle

[occitania]

Antwort auf Beitrag Nr.: 46.091.804 von kwhistler am 20.12.13 16:52:50

Salut mes ami(e)s

Ich trade nicht Oramed....égal ob es 1bissi runter geht...

Es kann nur ab jetzt auf 25 $ gehen

Es gibt´s kaum ORMP aktien...Deswegen...

Sie können sich von mir aus sich kloppen...Meine steht

Und Ubernahme kann jetzt auch noch kommen + Patente...

Kurzziel--->307 $ ...gelle

à bientôt
OC

Ich gehe früh aus dem Firma raus...um 20.00 uhr mache ich Feierabends...

Es ist der Hammer...Ich kriege mich nicht mehr an...

[kwhistler]

Antwort auf Beitrag Nr.: 46.091.746 von reaaalist am 20.12.13 16:47:59

was ein geiler Tag - werde demnächst wieder einsteigen - das ist sicher!!!!

[reaaalist]

Antwort auf Beitrag Nr.: 46.091.556 von occitania am 20.12.13 16:35:35

Was 1 Glück...oder um 13.00 uhr noch gekauft...

Moin Occi,

du hast zur Zeit aber wirklich ein glückliches Händchen!
ich dachte schon du hast die News vorzeitig von Muddi per Mail bekommen

Gruß r

[occitania]

Antwort auf Beitrag Nr.: 46.091.248 von reaaalist am 20.12.13 16:10:37

Salut reaaalist


Der Hammer...Ich habe mir gedacht ...Oramed und Muddi hat immer gut gemeint mir mir

Aber...Ich habe mich Gedanke gemacht über deine Posting...Und Geschenke von Muddi...

Die list bestimmt mit...Danke Muddi...

Was 1 Glück...oder um 13.00 uhr noch gekauft...

Ich habe in Dienstzimmer getanzt...

à bientôt
OC

Wir habenm uns es verdient...

Grüß an Kwhistly und Wanduhr...

[reaaalist]

Antwort auf Beitrag Nr.: 46.090.966 von kwhistler am 20.12.13 15:47:03

Die streiten sich um die letzten paar Aktien!

gibt nur ca 8 Millionen

Gruß r

[reaaalist]

Antwort auf Beitrag Nr.: 46.090.966 von kwhistler am 20.12.13 15:47:03

wow

was für ein Volumen!



ist ja fast schon wie bei der Telekom

[reaaalist]

Antwort auf Beitrag Nr.: 46.090.916 von kwhistler am 20.12.13 15:43:04

Hier die News

Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes



Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January


JERUSALEM December 20, 2013-Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.



Patients were treated with a different dose of oral insulin at each study visit; blood glucose and insulin levels were then monitored for the ensuing five hours. Patient responses positively correlated with administered doses, as did the duration of the effect.



"Based on these and the notable results from our previous oral insulin trials in type 1 diabetes, we continue to move forward with this indication in parallel to our advanced clinical studies in type 2 diabetes," commented CEO Nadav Kidron.



Type 1 diabetes (T1DM) is an autoimmune disease wherein the body destroys its own insulin-producing cells, leaving patients completely dependent on external insulin sources. The disease, formerly known as juvenile diabetes, currently affects both young and adult populations. According to the International Diabetes Federation, T1DM is on the rise at a rate of 3% per year and currently affects approximately 36 million people worldwide - about 10% of the global diabetes population.



About ORMD-0801 Oral Insulin and T1DM



T1DM is currently treated with two types of insulin replacement therapies: long-acting insulin (basal) to help maintain stable insulin levels during fasting periods, and pre-meal insulin (bolus) doses. Oramed proposes to introduce ORMD-0801 to replace the mealtime (bolus) insulin doses, which would significantly reduce the number of daily injections. Additionally, oral administration offers the benefit of reduced systemic exposure and may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver. For more information on ORMD-0801, the content of which is not part of this press release, please visit http://oramed.com/index.php?page=14



About Oramed Pharmaceuticals



Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), which has been assessed in healthy volunteers (Phase 1b) and is currently being tested in T2DM patients (Phase 2a). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.



For more information, the content of which is not part of this press release, please visit www.oramed.com


Danke Muddi

[kwhistler]

Antwort auf Beitrag Nr.: 46.090.960 von reaaalist am 20.12.13 15:46:15

was ist den passiert